MM
MCID: MLT019
MIFTS: 83

Multiple Myeloma (MM) malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Neuronal diseases, Nephrological diseases, Bone diseases, Blood diseases, Immune diseases

Aliases & Classifications for Multiple Myeloma

Aliases & Descriptions for Multiple Myeloma:

Name: Multiple Myeloma 54 38 12 50 24 25 56 66 13 41 42 14 69
Plasma Cell Myeloma 12 50 56 52
Medullary Plasmacytoma 25 56 69
Plasma Cell Dyscrasia 50 25 69
Myelomatosis 50 25 56
Primary Systemic Amyloidosis 56 69
Primary Amyloidosis 56 69
Myeloma - Multiple 50 29
Kahler's Disease 25 56
Kahler Disease 50 25
Myeloma, Multiple Amyloidosis, Systemic, Included 54
Immunoglobulin Deposition Disease 69
Systemic Al Amyloidosis 56
Light-Chain Amyloidosis 56
Kahler-Bozzolo Disease 25
Plasma Cell Neoplasm 69
Plasma Cell Myelomas 25
Al Amyloidosis 56
Mm 66

Characteristics:

Orphanet epidemiological data:

56
multiple myeloma
Prevalence: 1-9/100000 (United States),1-9/100000 (Worldwide),1-5/10000 (Europe),1-9/100000 (France),1-9/100000 (Europe),1-9/100000 (Australia); Age of onset: Adult;
primary systemic amyloidosis
Inheritance: Not applicable;
al amyloidosis
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Adult;

HPO:

32
multiple myeloma:
Inheritance autosomal recessive inheritance somatic mutation


Classifications:



External Ids:

OMIM 54 254500
Disease Ontology 12 DOID:9538
ICD10 33 C90.0 C90.00
ICD9CM 35 203.0
MeSH 42 D009101
NCIt 47 C3242
ICD10 via Orphanet 34 E85.0 E85.1 E85.2 more
MESH via Orphanet 43 D009101 C531616
UMLS via Orphanet 70 C0026764 C0268381
UMLS 69 C0026764

Summaries for Multiple Myeloma

NIH Rare Diseases : 50 multiple myeloma is a form of cancer that occurs due to abnormal and uncontrolled growth of plasma cells in the bone marrow. some people with multiple myeloma, especially those with early stages of the condition, have no concerning signs or symptoms. when present, the most common symptom is anemia, which can be associated with fatigue and shortness of breath. other features of the condition may include multiple infections; abnormal bleeding; bone pain; weak and/or easily broken bones; and numbness and/or weakness of the arms and legs. the exact underlying cause of multiple myeloma is currently unknown. factors that are associated with an increased risk of developing multiple myeloma include increasing age, male sex, african american race, radiation exposure, a family history of the condition, obesity, and/or a personal history of monoclonal gammopathy of undetermined significance (mgus). treatment varies based on many factors, but may include one or more of the following interventions: chemotherapy, corticosteroid medications, targeted therapy, stem cell transplant, biological therapy, radiation therapy, surgery and/or watchful waiting. last updated: 3/12/2016

MalaCards based summary : Multiple Myeloma, also known as plasma cell myeloma, is related to igh-related multiple myeloma and plasmacytoma, and has symptoms including fatigue, bone pain and generalized muscle weakness. An important gene associated with Multiple Myeloma is LIG4 (DNA Ligase 4), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Aredia and Busulfex have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are behavior/neurological and growth/size/body region

Disease Ontology : 12 A myeloid neoplasm that is located in the plasma cells in bone marrow.

Genetics Home Reference : 25 Multiple myeloma is a cancer that develops in the bone marrow, the spongy tissue found in the center of most bones. The bone marrow produces red blood cells, which carry oxygen throughout the body; white blood cells, which form the body's defenses (immune system); and platelets, which are necessary for blood clotting.

OMIM : 54 Multiple myeloma is a neoplastic plasma cell disorder characterized by clonal proliferation of malignant plasma cells... (254500) more...

MedlinePlus : 41 multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. these cells are part of your immune system, which helps protect the body from germs and other harmful substances. in time, myeloma cells collect in the bone marrow and in the solid parts of bones. no one knows the exact causes of multiple myeloma, but it is more common in older people and african americans. it can run in families. common symptoms may include bone pain, often in the back or ribs broken bones weakness or fatigue weight loss frequent infections and fevers feeling very thirsty frequent urination doctors diagnose multiple myeloma using lab tests, imaging tests, and a bone marrow biopsy. your treatment depends on how advanced the disease is and whether you have symptoms. if you have no symptoms, you may not need treatment right away. if you have symptoms, you may have chemotherapy, stem cell transplantation, radiation, or targeted therapy. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

UniProtKB/Swiss-Prot : 66 Multiple myeloma: A malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia.

Wikipedia : 71 Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood... more...

Related Diseases for Multiple Myeloma

Diseases in the Multiple Myeloma family:

Igh-Related Multiple Myeloma

Diseases related to Multiple Myeloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 409)
id Related Disease Score Top Affiliating Genes
1 igh-related multiple myeloma 11.9
2 plasmacytoma 11.6
3 plasma cell leukemia 11.6
4 light chain deposition disease 11.5
5 monoclonal gammopathy of uncertain significance 11.5
6 hematopoietic stem cell transplantation 11.2
7 plasma cell neoplasm 11.2
8 cryoglobulinemia 11.2
9 epidermolysis bullosa acquisita 11.2
10 hypoaldosteronism 11.2
11 smoldering myeloma 11.2
12 indolent myeloma 10.9
13 microphthalmia, isolated 6 10.9
14 medial medullary syndrome 10.8
15 miyoshi muscular dystrophy 1 10.8
16 extramedullary plasmacytoma 10.7
17 leukemia 10.4
18 lymphoma 10.4
19 polycystic bone disease 10.3 CCND1 FGFR3 IRF4 NCAM1
20 keratoconus 10.3 DKK1 IL6 IL6R
21 theileriasis 10.3 CCND1 IL6 IL6R NCAM1
22 amyloidosis 10.3
23 endotheliitis 10.2
24 ethmoid sinus schneiderian papilloma 10.2 CD19 FGFR3 IL6 NCAM1
25 verrucous carcinoma 10.2 CD19 MCL1 NCAM1
26 childhood pleomorphic rhabdomyosarcoma 10.2 CD19 IL6 NCAM1
27 gingival recession 10.2 CCND1 IRF4 MCL1
28 pulmonary fibrosis, idiopathic 10.1 CCND1 CCND3 CD19 IRF4 MCL1
29 neuropathy 10.1
30 ectodermal dysplasia 10.1 CCND1 CDK4 IRF4
31 macroglobulinemia 10.1
32 al amyloidosis 10.1
33 extraocular retinoblastoma 10.1 CCND1 CCND3 CDK4
34 chronic lymphocytic leukemia 10.0
35 integumentary system benign neoplasm 10.0 CCND1 CCND3 CDK4
36 glomerulonephritis 10.0
37 post-surgical hypoinsulinemia 10.0 CCND1 CCND3 CDK4
38 purpura 10.0
39 cutis laxa 10.0
40 hodgkin lymphoma 10.0
41 melanoma metastasis 10.0 CCND1 CCND3 CD19 CDK4 MCL1
42 acquired cutis laxa 9.9
43 osteonecrosis 9.9
44 fanconi syndrome 9.9
45 hepatitis 9.9
46 osteonecrosis of the jaw 9.9
47 acute leukemia 9.9
48 hypoxia 9.9
49 myelodysplastic syndrome 9.9
50 arthritis 9.9

Graphical network of the top 20 diseases related to Multiple Myeloma:



Diseases related to Multiple Myeloma

Symptoms & Phenotypes for Multiple Myeloma

Symptoms by clinical synopsis from OMIM:

254500

Clinical features from OMIM:

254500

Human phenotypes related to Multiple Myeloma:

56 32 (show top 50) (show all 80)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 56 32 Frequent (79-30%),Very frequent (99-80%) HP:0012378
2 bone pain 56 32 Frequent (79-30%) HP:0002653
3 generalized muscle weakness 56 32 Frequent (79-30%) HP:0003324
4 osteopenia 56 32 Very frequent (99-80%) HP:0000938
5 splenomegaly 56 32 Very rare (<4-1%) HP:0001744
6 nephropathy 56 32 Frequent (79-30%),Frequent (79-30%) HP:0000112
7 anemia 56 32 Frequent (79-30%) HP:0001903
8 weight loss 56 32 Occasional (29-5%) HP:0001824
9 pathologic fracture 56 32 Very frequent (99-80%) HP:0002756
10 decreased antibody level in blood 56 32 Frequent (79-30%),Occasional (29-5%) HP:0004313
11 nephrotic syndrome 56 32 Frequent (79-30%),Frequent (79-30%) HP:0000100
12 paresthesia 56 32 Occasional (29-5%) HP:0003401
13 elevated serum creatinine 56 32 Frequent (79-30%) HP:0003259
14 hypercalcemia 56 32 Occasional (29-5%) HP:0003072
15 abnormality of the bladder 56 32 Occasional (29-5%) HP:0000014
16 acute kidney injury 56 32 Frequent (79-30%) HP:0001919
17 lymphadenopathy 56 32 Very rare (<4-1%),Frequent (79-30%) HP:0002716
18 tall stature 56 32 Occasional (29-5%) HP:0000098
19 pleural effusion 56 32 Very rare (<4-1%),Occasional (29-5%) HP:0002202
20 functional abnormality of the gastrointestinal tract 56 32 Occasional (29-5%) HP:0012719
21 increased iga level 56 32 Occasional (29-5%) HP:0003261
22 vertebral compression fractures 56 32 Occasional (29-5%) HP:0002953
23 spinal cord compression 56 32 Occasional (29-5%) HP:0002176
24 increased igg level 56 32 Frequent (79-30%) HP:0003237
25 multiple myeloma 56 32 Frequent (79-30%) HP:0006775
26 hyperproteinemia 56 32 Frequent (79-30%) HP:0002152
27 abnormality of vitamin b12 metabolism 56 32 Occasional (29-5%) HP:0004341
28 arthralgia 56 Frequent (79-30%)
29 constipation 56 Frequent (79-30%)
30 dyspnea 56 Frequent (79-30%)
31 chronic constipation 56 Frequent (79-30%)
32 osteoarthritis 56 Occasional (29-5%)
33 hypertension 56 Occasional (29-5%)
34 macroglossia 56 Occasional (29-5%)
35 hepatomegaly 56 Frequent (79-30%)
36 malabsorption 56 Occasional (29-5%)
37 renal insufficiency 56 Frequent (79-30%)
38 proteinuria 56 Frequent (79-30%)
39 hypertrophic cardiomyopathy 56 Very frequent (99-80%)
40 arrhythmia 56 Frequent (79-30%)
41 hepatitis 56 Occasional (29-5%)
42 abnormal blistering of the skin 56 Occasional (29-5%)
43 congestive heart failure 56 Frequent (79-30%)
44 goiter 56 Occasional (29-5%)
45 keratoconjunctivitis sicca 56 Occasional (29-5%)
46 hematuria 56 Occasional (29-5%)
47 xerostomia 56 Occasional (29-5%)
48 purpura 56 Occasional (29-5%)
49 gastrointestinal hemorrhage 56 Occasional (29-5%)
50 papule 56 Occasional (29-5%)

MGI Mouse Phenotypes related to Multiple Myeloma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.22 CCND1 CCND3 CD19 CDK4 CRBN FGFR3
2 growth/size/body region MP:0005378 10.18 IL6 IL6R LIG4 NBEA NSD2 CCND1
3 endocrine/exocrine gland MP:0005379 10.09 CCND1 CCND3 CDK4 CRBN IL6 IL6R
4 hematopoietic system MP:0005397 10.07 CCND1 CCND3 CD19 CDK4 FGFR3 IL6
5 immune system MP:0005387 10.02 MCL1 CCND1 CCND3 CD19 CDK4 FGFR3
6 digestive/alimentary MP:0005381 10 NSD2 CCND1 CD19 CDK4 FGFR3 IL6
7 mortality/aging MP:0010768 9.97 CCND1 CCND3 CD19 CDK4 DKK1 FGFR3
8 liver/biliary system MP:0005370 9.8 CDK4 CRBN IL6 IL6R LIG4 CCND3
9 neoplasm MP:0002006 9.61 CCND1 CCND3 CD19 CDK4 FGFR3 IL6
10 normal MP:0002873 9.23 CCND1 CCND3 CD19 CDK4 DAZAP2 FGFR3

Drugs & Therapeutics for Multiple Myeloma

FDA approved drugs:

(show all 17)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Aredia 17 46 PAMIDRONATE DISODIUM Chiron Approved August 1996
2
Busulfex 17 46 BUSULFAN Orphan Medical Approved February 1999
3
Doxil 17 46 DOXORUBICIN HYDROCHLORIDE Alza Approved June 1999
4
Evista 17 46 RALOXIFENE HYDROCHLORIDE Eli Lilly Approved September 2007
5
Farydak 17 46 PANOBINOSTAT LACTATE Novartis Approved February 2015
6
Kyprolis 17 46 CARFILZOMIB Onyx Pharmaceuticals Approved July 2012
7
Mozobil 17 46 PLERIXAFOR Genzyme Approved December 2008
8
Pomalyst 17 46 POMALIDOMIDE Celgene Approved February 2013
9
Revlimid 17 46 LENALIDOMIDE Celgene Approved June 2013
10
Sprycel 17 46 DASATINIB Bristol-Myers Squibb Approved June 2006
11
Subsys 17 FENTANYL Insys Therapeutics Approved January of 2012
12
Velcade 17 46 BORTEZOMIB Millennium Pharmaceuticals Approved May 2003
13
Xgeva 17 46 DENOSUMAB Amgen Approved June 2013/ Approved November 2010
14
Zoladex 17 46 GOSERELIN ACETATE AstraZeneca Approved January 1996
15
Zometa 17 46 ZOLEDRONIC ACID Novartis Approved August 2001/ Approved February 2002
16
Adempas 17 RIOCIGUAT Bayer Healthcare Pharmaceuticals Approved October 2013
17
Vibativ 17 * TELAVANCIN * TELAVANCIN HYDROCHLORIDE Theravance Approved June 2013

Drugs for Multiple Myeloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 684)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 148-82-3 4053 460612
4
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
5
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6 23925
6
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
7
Vidarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24356-66-9 32326 21704
8
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 55-98-1 2478
9
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
10
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 179324-69-7 387447 93860
11
Mesna Approved Phase 4,Phase 3,Phase 2,Phase 1 3375-50-6 598
12
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
13
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 191732-72-6 216326
14
Panobinostat Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 404950-80-7 6918837
15
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
16
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
17
Phentolamine Approved Phase 4 50-60-2 5775
18
Thiotepa Approved Phase 4,Phase 2,Phase 1 52-24-4 5453
19
Tazobactam Approved Phase 4,Phase 3 89786-04-9 123630
20
Piperacillin Approved Phase 4,Phase 3 66258-76-2 43672
21
Apixaban Approved Phase 4,Phase 3,Phase 2 503612-47-3 10182969
22
Liraglutide Approved Phase 4 204656-20-2
23
Pirarubicin Investigational Phase 4 72496-41-4
24
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
25 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1177-87-3
26 Epoetin alfa Phase 4,Phase 3,Phase 2 113427-24-0
27 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Myeloma Proteins Phase 4,Phase 3,Phase 2,Phase 1
32 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Hematinics Phase 4,Phase 3,Phase 2
35 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
36 Histone Deacetylase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
37 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Dexamethasone 21-phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Diphosphonates Phase 4,Phase 3,Phase 2,Phase 1
40 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Paraproteins Phase 4,Phase 3,Phase 2,Phase 1
42 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Hypoglycemic Agents Phase 4,Phase 1,Phase 2
47 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2294)
id Name Status NCT ID Phase
1 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4
2 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4
3 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4
4 Pseudohyponatremia of Multiple Myeloma is True Hyponatremia Unknown status NCT01425606 Phase 4
5 Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America Completed NCT02559583 Phase 4
6 Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma Completed NCT01083602 Phase 4
7 A Multiple Myeloma Trial in Patients With Bone Metastases Completed NCT00104104 Phase 4
8 A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma Completed NCT02268890 Phase 4
9 Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4
10 Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients Completed NCT00622505 Phase 4
11 Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib Completed NCT01060202 Phase 4
12 A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure Completed NCT01241396 Phase 4
13 Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients. Completed NCT01026701 Phase 4
14 Quality of Life in Multiple Myeloma Patients Treated With Bortezomib Completed NCT01021592 Phase 4
15 A Retreatment Study With Bortezomib for Multiple Myeloma Completed NCT01030302 Phase 4
16 Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma Completed NCT02474563 Phase 4
17 Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability Completed NCT00257114 Phase 4
18 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4
19 An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade Completed NCT01675245 Phase 4
20 REmoval of Free Light Chains. A COmpaRison of Three Different dialyzERs Completed NCT02950389 Phase 4
21 VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands Completed NCT00440765 Phase 4
22 ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies. Completed NCT00440479 Phase 4
23 Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS) Completed NCT01005628 Phase 4
24 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4
25 Retrospective Survey of Re-treatment With Bortezomib Completed NCT01524445 Phase 4
26 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4
27 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4
28 Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation Completed NCT01339572 Phase 4
29 FREE Study - Fracture Reduction Evaluation Completed NCT00211211 Phase 4
30 Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients Completed NCT00195533 Phase 4
31 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
32 Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation Completed NCT01738373 Phase 4
33 Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4
34 CAFE Study - Cancer Patient Fracture Evaluation Completed NCT00211237 Phase 4
35 Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma Recruiting NCT02773550 Phase 4
36 Modified Bortezomib-based Combination Therapy for Multiple Myeloma Recruiting NCT02559154 Phase 4
37 Prolonged Protection From Bone Disease in Multiple Myeloma Recruiting NCT02286830 Phase 4
38 PDD vs PAD to Treat Initially Diagnosed MM Recruiting NCT02577783 Phase 4
39 Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse Active, not recruiting NCT01087008 Phase 4
40 Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Active, not recruiting NCT01731886 Phase 4
41 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Not yet recruiting NCT02958969 Phase 4
42 An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (TOURMALINE MM-6) Not yet recruiting NCT03173092 Phase 4
43 Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients. Not yet recruiting NCT02006225 Phase 4
44 Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat Not yet recruiting NCT02920190 Phase 4
45 Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy Terminated NCT01100879 Phase 4
46 A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B Terminated NCT02608060 Phase 4
47 Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. Withdrawn NCT00242528 Phase 4
48 Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma Withdrawn NCT01410929 Phase 4
49 Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma Unknown status NCT00002653 Phase 3
50 Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma Unknown status NCT00014339 Phase 3

Search NIH Clinical Center for Multiple Myeloma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Multiple Myeloma cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: multiple myeloma

Genetic Tests for Multiple Myeloma

Genetic tests related to Multiple Myeloma:

id Genetic test Affiliating Genes
1 Multiple Myeloma 29 24 LIG4

Anatomical Context for Multiple Myeloma

MalaCards organs/tissues related to Multiple Myeloma:

39
Bone, Bone Marrow, Testes, T Cells, B Cells, Myeloid, Endothelial

The Foundational Model of Anatomy Ontology organs/tissues related to Multiple Myeloma:

18
The Plasma Cells In Bone Marrow
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Multiple Myeloma:
id Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Multiple Myeloma

Articles related to Multiple Myeloma:

(show top 50) (show all 3441)
id Title Authors Year
1
The effect of S1P receptor signaling pathway on the survival and drug resistance in multiple myeloma cells. ( 27785703 )
2017
2
Asymmetric Deep Stromal Keratopathy in a Patient With Multiple Myeloma. ( 28079685 )
2017
3
The Coexistence of Multiple Myeloma-associated Amyloid Light-chain Amyloidosis and Fabry Disease in a Hemodialysis Patient. ( 28381753 )
2017
4
Racial disparities in treatment use for multiple myeloma. ( 28085188 )
2017
5
Inhibiting the osteocyte specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. ( 28515094 )
2017
6
Current Strategies for the Immunotherapy of Multiple Myeloma. ( 28090624 )
2017
7
NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase. ( 28086949 )
2017
8
Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma. ( 28083618 )
2017
9
A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma. ( 28088784 )
2017
10
Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma. ( 28527129 )
2017
11
Identification of a novel microRNA, miR-4449, as a potential blood based marker in multiple myeloma. ( 27155004 )
2017
12
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. ( 28082445 )
2017
13
Disappearance of acquired hemophilia A after complete remission in a Multiple Myeloma patient. ( 28077343 )
2017
14
Identification of precision treatment strategies for relapsed/ refractory multiple myeloma by functional drug sensitivity testing. ( 28525891 )
2017
15
Geriatric Assessment to Predict Survival and Risk of Serious Adverse Events in Elderly Newly Diagnosed Multiple Myeloma Patients: A Multicenter Study in China. ( 28091402 )
2017
16
Pharmacogenomics and chemical library screens reveal a novel SCF(SKP2) inhibitor that overcomes Bortezomib resistance in multiple myeloma. ( 27677741 )
2017
17
Immunoglobulin D Multiple Myeloma Presenting as Spontaneous Fracture. ( 28512409 )
2017
18
RGS1 expression is associated with poor prognosis in multiple myeloma. ( 27445341 )
2017
19
MicroRNA-1271 inhibits proliferation and promotes apoptosis of multiple myeloma cells through inhibiting smoothened-mediated Hedgehog signaling pathway. ( 27959416 )
2017
20
Risk of vertebral compression fractures in multiple myeloma patients: A finite-element study. ( 28079810 )
2017
21
G-CSF improves safety when you start the day after autologous transplant in multiple myeloma. ( 28509594 )
2017
22
Return to the Primary Acute Care Service Among Patients With Multiple Myeloma on an Acute Inpatient Rehabilitation Unit. ( 28082181 )
2017
23
Why Value Framework Assessments Arrive at Different Conclusions: A Multiple Myeloma Case Study. ( 28535102 )
2017
24
Dermoscopy of cutaneous involvement by multiple myeloma. ( 28087038 )
2017
25
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. ( 28513828 )
2017
26
Upregulated lncRNA-PCAT1 is closely related to clinical diagnosis of multiple myeloma as a predictive biomarker in serum. ( 28085010 )
2017
27
Crohn's disease and smoldering multiple myeloma: a case report and literature review. ( 28522957 )
2017
28
Utilizing next-generation sequencing in the management of multiple myeloma. ( 28524737 )
2017
29
Genetic deletion of sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth. ( 28529307 )
2017
30
EphA4 promotes cell proliferation and cell adhesion-mediated drug resistance via the AKT pathway in multiple myeloma. ( 28351297 )
2017
31
bFGF Polymorphism Is Associated with Disease Progression and Response to Chemotherapy in Multiple Myeloma Patients. ( 28373444 )
2017
32
RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response. ( 27909306 )
2017
33
Immunoglobulin A Lambda Multiple Myeloma in a Patient with HIV: An Unusual Cause of Massive Ascites. ( 28512393 )
2017
34
Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV). ( 28534173 )
2017
35
Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma. ( 28068938 )
2017
36
CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma. ( 28529638 )
2017
37
A family-centered intervention for the transition to living with multiple myeloma as a chronic illness: A pilot study. ( 28532734 )
2017
38
hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10. ( 28000886 )
2017
39
Is immunotherapy here to stay in multiple myeloma? ( 28082344 )
2017
40
New Treatment Options for the Management of Multiple Myeloma. ( 28515251 )
2017
41
Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation. ( 28512269 )
2017
42
The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. ( 28522572 )
2017
43
Haematological cancer: Pembrolizumab is effective in multiple myeloma. ( 28534530 )
2017
44
Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib. ( 28521480 )
2017
45
Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. ( 28063964 )
2017
46
Two Secondary Primary Malignancies after Bortezomib Therapy for Multiple Myeloma: A Single-center Experience. ( 28091419 )
2017
47
Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma. ( 26033514 )
2017
48
Carfilzomib, lenalidomide, and dexamethasone in patients with heavily-pretreated multiple myeloma: A phase 1 study in Japan. ( 28092421 )
2017
49
Effect of Cytokine Genes in the Pathogenesis and on the Clinical Parameters for the Treatment of Multiple Myeloma. ( 27611810 )
2017
50
Gemcitabine, busulfan, and melphalan conditioning for autologous stem-cell transplants in multiple myeloma. ( 28522109 )
2017

Variations for Multiple Myeloma

ClinVar genetic disease variations for Multiple Myeloma:

6 (show top 50) (show all 132)
id Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
2 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
3 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
4 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
5 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
6 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
7 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
8 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
9 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh37 Chromosome 11, 533467: 533467
10 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Pathogenic/Likely pathogenic rs121917759 GRCh37 Chromosome 11, 533466: 533466
11 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
12 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121918464 GRCh37 Chromosome 12, 112888210: 112888210
13 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
14 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
15 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
16 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
17 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
18 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic/Likely pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
19 BRAF NM_004333.4(BRAF): c.1397G> T (p.Gly466Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913351 GRCh37 Chromosome 7, 140481411: 140481411
20 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
21 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
22 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
23 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154
24 BRAF NM_004333.4(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
25 IDH2 NM_002168.3(IDH2): c.419G> A (p.Arg140Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121913502 GRCh37 Chromosome 15, 90631934: 90631934
26 FGFR3 NM_000142.4(FGFR3): c.1948A> G (p.Lys650Glu) single nucleotide variant Pathogenic/Likely pathogenic rs78311289 GRCh37 Chromosome 4, 1807889: 1807889
27 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913482 GRCh37 Chromosome 4, 1803564: 1803564
28 FGFR3 FGFR3, FGFR3/IGH FUSION undetermined variant Pathogenic
29 CDK4 NM_000075.3(CDK4): c.70C> T (p.Arg24Cys) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs11547328 GRCh37 Chromosome 12, 58145431: 58145431
30 CDK4 NM_000075.3(CDK4): c.71G> A (p.Arg24His) single nucleotide variant Likely pathogenic,risk factor rs104894340 GRCh37 Chromosome 12, 58145430: 58145430
31 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
32 MYD88 NM_001172567.1(MYD88): c.818T> C (p.Leu273Pro) single nucleotide variant Pathogenic/Likely pathogenic rs387907272 GRCh37 Chromosome 3, 38182641: 38182641
33 NRAS NM_002524.4(NRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913237 GRCh37 Chromosome 1, 115258747: 115258747
34 BRAF NM_004333.4(BRAF): c.1787G> T (p.Gly596Val) single nucleotide variant Pathogenic/Likely pathogenic rs397507483 GRCh37 Chromosome 7, 140453148: 140453148
35 NRAS NM_002524.4(NRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913250 GRCh37 Chromosome 1, 115258748: 115258748
36 NRAS NM_002524.4(NRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913250 GRCh37 Chromosome 1, 115258748: 115258748
37 NRAS NM_002524.4(NRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913237 GRCh37 Chromosome 1, 115258747: 115258747
38 PTPN11 NM_002834.4(PTPN11): c.1508G> T (p.Gly503Val) single nucleotide variant Likely pathogenic rs397507546 GRCh37 Chromosome 12, 112926888: 112926888
39 BRAF NM_004333.4(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
40 BRAF NM_004333.4(BRAF): c.1780G> A (p.Asp594Asn) single nucleotide variant Pathogenic/Likely pathogenic rs397516896 GRCh37 Chromosome 7, 140453155: 140453155
41 KRAS NM_033360.3(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 GRCh37 Chromosome 12, 25380275: 25380275
42 BRAF NM_004333.4(BRAF): c.1741A> C (p.Asn581His) single nucleotide variant Likely pathogenic rs180177040 GRCh37 Chromosome 7, 140453987: 140453987
43 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
44 BRAF NM_004333.4(BRAF): c.1790T> A (p.Leu597Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
45 TP53 NM_000546.5(TP53): c.422G> A (p.Cys141Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587781288 GRCh37 Chromosome 17, 7578508: 7578508
46 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
47 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
48 NRAS NM_002524.4(NRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913250 GRCh37 Chromosome 1, 115258748: 115258748
49 BRAF NM_004333.4(BRAF): c.1742A> G (p.Asn581Ser) single nucleotide variant Likely pathogenic rs121913370 GRCh37 Chromosome 7, 140453193: 140453193
50 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh38 Chromosome 11, 534285: 534285

Copy number variations for Multiple Myeloma from CNVD:

7 (show top 50) (show all 302)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13351 1 1 125000000 Gain Multiple myeloma
2 14061 1 103799708 118390708 Loss Multiple myeloma
3 14338 1 107200000 120600000 Loss and deletion Multiple myeloma
4 14696 1 110000000 184000000 Gain SELL Multiple myeloma
5 16446 1 124300000 247249719 Rearrangement Multiple myeloma
6 17400 1 142600000 156500000 Gain and amplification Multiple myeloma
7 17467 1 142902432 245422432 Gain Multiple myeloma
8 20609 1 153300000 154800000 Gain AIM2 Multiple myeloma
9 20611 1 153300000 154800000 Gain EST1B Multiple myeloma
10 20700 1 1536308 6536308 Loss Multiple myeloma
11 20848 1 154800000 157300000 Gain UFC1 Multiple myeloma
12 20849 1 154800000 158800000 Gain CAPON Multiple myeloma
13 20882 1 155000000 156500000 Gain and amplification Multiple myeloma
14 26152 1 197500000 205300000 Gain CHI3L1 Multiple myeloma
15 26153 1 197500000 205300000 Gain PTPN7 Multiple myeloma
16 26162 1 197500000 222100000 Gain GUK1 Multiple myeloma
17 29497 1 23265113 23869113 Loss Multiple myeloma
18 29829 1 236600000 249250621 Gain and amplification Multiple myeloma
19 31636 1 2900000 120700000 Gain CD53 Multiple myeloma
20 31729 1 30200000 32400000 Loss and deletion Multiple myeloma
21 31749 1 30500000 184000000 Gain Multiple myeloma
22 33943 1 50669458 53683458 Loss Multiple myeloma
23 33949 1 50700000 59000000 Loss and deletion Multiple myeloma
24 35189 1 60900000 69500000 Gain NFIA Multiple myeloma
25 36791 1 80821425 83677425 Loss Multiple myeloma
26 36969 1 84171854 96213854 Loss Multiple myeloma
27 37035 1 84700000 88100000 Gain Multiple myeloma
28 37040 1 84700000 94500000 Gain DISC1 Multiple myeloma
29 37519 1 9200000 12700000 Loss and deletion Multiple myeloma
30 37525 10 30762871 30790767 Gain EST Multiple myeloma
31 38898 10 105800000 114900000 Loss and deletion Multiple myeloma
32 40402 10 127500000 135534747 Loss and deletion Multiple myeloma
33 41379 10 17300000 22600000 Gain and amplificati on Multiple myeloma
34 48571 11 100828925 102320925 Loss ANGPTL5 Multiple myeloma
35 48572 11 100828925 102320925 Loss BIRC2 Multiple myeloma
36 48573 11 100828925 102320925 Loss BIRC3 Multiple myeloma
37 48574 11 100828925 102320925 Loss KIAA1377 Multiple myeloma
38 48575 11 100828925 102320925 Loss MMP1 Multiple myeloma
39 48576 11 100828925 102320925 Loss MMP10 Multiple myeloma
40 48577 11 100828925 102320925 Loss MMP12 Multiple myeloma
41 48578 11 100828925 102320925 Loss MMP13 Multiple myeloma
42 48579 11 100828925 102320925 Loss MMP20 Multiple myeloma
43 48580 11 100828925 102320925 Loss MMP27 Multiple myeloma
44 48581 11 100828925 102320925 Loss MMP3 Multiple myeloma
45 48582 11 100828925 102320925 Loss MMP7 Multiple myeloma
46 48583 11 100828925 102320925 Loss MMP8 Multiple myeloma
47 48584 11 100828925 102320925 Loss PORIMIN Multiple myeloma
48 48585 11 100828925 102320925 Loss TRPC6 Multiple myeloma
49 48586 11 100828925 102320925 Loss YAP1 Multiple myeloma
50 49668 11 110000000 112800000 Gain POU2AF1 Multiple myeloma

Expression for Multiple Myeloma

Search GEO for disease gene expression data for Multiple Myeloma.

Pathways for Multiple Myeloma

Pathways related to Multiple Myeloma according to GeneCards Suite gene sharing:

(show all 25)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.96 BST2 C1orf35 CCND1 CD19 FGFR3 IL6
2
Show member pathways
13.12 BST2 CCND1 FGFR3 IL6 IL6R IRF4
3 12.38 CCND1 CCND3 CDK4 LIG4
4 12.31 CCND1 CCND3 CDK4 DKK1
5 12.29 CCND1 CCND3 CDK4 IL6
6
Show member pathways
11.99 CCND1 CCND3 CDK4 FGFR3
7
Show member pathways
11.79 CCND1 CCND3 IL6 IL6R MCL1
8 11.78 CCND1 CDK4 IL6
9 11.76 CD19 IL6 IL6R
10 11.76 CCND1 CCND3 CD19 CDK4 FGFR3 IL6
11 11.75 CD19 IL6 NCAM1
12
Show member pathways
11.73 IL6 IL6R IRF4
13 11.69 CCND1 CCND3 CDK4
14
Show member pathways
11.67 IL6 IL6R MCL1
15
Show member pathways
11.64 CCND1 CCND3 CDK4
16 11.59 CCND1 CDK4 FGFR3
17 11.44 CCND1 CDK4 IL6
18 11.44 CD19 IL6 IRF4 NCAM1
19 11.41 CCND1 IL6 IL6R IRF4 MCL1
20 11.39 CCND1 IL6 IL6R
21 11.38 CCND1 IL6 MCL1
22 11.31 DKK1 IL6 IL6R
23 11.25 CCND1 CCND3 CDK4
24 11.09 CCND1 CCND3 IL6
25 11 CCND1 CCND3 CDK4

GO Terms for Multiple Myeloma

Cellular components related to Multiple Myeloma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.55 BST2 FGFR3 IL6R MICA NCAM1
2 interleukin-6 receptor complex GO:0005896 8.96 IL6 IL6R
3 cyclin-dependent protein kinase holoenzyme complex GO:0000307 8.8 CCND1 CCND3 CDK4

Biological processes related to Multiple Myeloma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.85 CCND1 CDK4 FGFR3 IL6 IL6R
2 response to cytokine GO:0034097 9.5 IL6 IL6R MCL1
3 positive regulation of chemokine production GO:0032722 9.48 IL6 IL6R
4 positive regulation of leukocyte chemotaxis GO:0002690 9.43 IL6 IL6R
5 regulation of insulin receptor signaling pathway GO:0046626 9.4 CCND3 CDK4
6 interleukin-6-mediated signaling pathway GO:0070102 9.37 IL6 IL6R
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.33 FGFR3 IL6 IL6R
8 T-helper 17 cell lineage commitment GO:0072540 9.26 IL6 IRF4
9 positive regulation of tyrosine phosphorylation of Stat3 protein GO:0042517 9.13 FGFR3 IL6 IL6R
10 hepatic immune response GO:0002384 8.62 IL6 IL6R

Molecular functions related to Multiple Myeloma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein serine/threonine kinase regulator activity GO:0016538 9.26 CCND1 CDK4
2 interleukin-6 receptor binding GO:0005138 8.96 IL6 IL6R
3 cyclin-dependent protein serine/threonine kinase activity GO:0004693 8.8 CCND1 CCND3 CDK4
4 protein binding GO:0005515 10.09 BST2 C1orf35 CCND1 CCND3 CD19 CDK4

Sources for Multiple Myeloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....